Physician profile
Michael S Basch
NPI 1790889350
$5,833.27
in general payments reported to CMS, 2019-2025
44 companies · $804 in 2025
The $804 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $1,568 · 2021: $349 · 2022: $376 · 2023: $854 · 2024: $755 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $698.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $649.17 | 2019-2020 | |
| Novo Nordisk INC | $545.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $396.78 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $351.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $288.68 | 2019-2024 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $279.16 | 2019-2024 | Spravato |
| Abbvie INC. | $273.94 | 2020-2025 | Dalvance |
| Harmony Biosciences LLC | $271.02 | 2024-2025 | |
| Abbott Laboratories | $267.14 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $229.40 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $205.03 | 2019-2021 | |
| Medtronic, INC. | $172.78 | 2023 | Intellis Adaptivestim |
| Mannkind Corporation | $147.75 | 2019-2023 | Afrezza |
| Lilly USA, LLC | $142.72 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Basch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.